Rather Than Rs1800796 Polymorphism, Expression of Interleukin-6 is Associated with Disease Progression of Chronic HBV Infection in a Chinese Han Population

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2013 Dec 28

PMID 24371367

Citations 13

Authors

Shengli Tang

Zhisu Liu

Yongxi Zhang

Yueming He

Dingyu Pan

Yuanyuan Liu

Quanyan Liu

Zhonglin Zhang

Yufeng Yuan

Affiliations

Soon will be listed here.

Abstract

Interleukin-6 plays an important role in chronic inflammation as well as tumor growth and progression. Here, a case-control study was undertaken to investigate the association of rs1800796 polymorphism of IL-6 gene and serum levels with disease progression of chronic HBV infection. Rs1800796 polymorphism was genotyped in 641 Chinese Han patients with chronic HBV infection, including 23 IT, 25 IC, 292 CHB, 153 LC, and 148 HCC patients and 265 healthy controls. Serum IL-6 levels were measured in 23 IT, 25 IC, 47 CHB, 41 LC, and 49 HCC patients and 45 healthy controls, and the classifications of HCC were accorded to BCLC staging system. We found no significant association between rs1800796 polymorphism and disease progression of chronic HBV infection; however, serum IL-6 levels showed significant statistical differences between patients with CHB, LC, and HCC. Moreover, statistical differences can be observed in patients with terminal stage HCC compared with those of early to intermediate or advanced stage HCC. Our findings suggest that rs1800796 polymorphism unlikely contribute significantly to affect the progression of chronic HBV infection, and serum IL-6 levels can act as a useful indicator for disease progression and severity of chronic HBV infection.

Citing Articles

The Role of Interleukins in HBV Infection: A Narrative Review.

Dimitriadis K, Katelani S, Pappa M, Fragkoulis G, Androutsakos T J Pers Med. 2023; 13(12).

PMID: 38138902 PMC: 10744424. DOI: 10.3390/jpm13121675.

Effect of aerobic exercise training on the fat fraction of the liver in persons with chronic hepatitis B and hepatic steatosis: Trial protocol for a randomized controlled intervention trial- The FitLiver study.

Jespersen S, Plomgaard P, Madsbad S, Hansen A, Bandholm T, Pedersen B Trials. 2023; 24(1):398.

PMID: 37312098 PMC: 10262472. DOI: 10.1186/s13063-023-07385-y.

Interleukin-6 Induced Proliferation Is Attenuated by Transforming Growth Factor-β-Induced Signaling in Human Hepatocellular Carcinoma Cells.

Srivastava A, Sharma H, Khanna S, Sadhu Balasundaram T, Chowdhury S, Chowdhury R Front Oncol. 2022; 11:811941.

PMID: 35127527 PMC: 8810489. DOI: 10.3389/fonc.2021.811941.

IL-6 and IL-10 gene polymorphisms and cirrhosis of liver risk from a comprehensive analysis.

Zheng M, Fang W, Yu M, Ding R, Zeng H, Huang Y BMC Endocr Disord. 2021; 21(1):242.

PMID: 34886817 PMC: 8656043. DOI: 10.1186/s12902-021-00906-3.

Association Between Serum IL-6, IL-10, IL-12, and IL-23 Levels and Severity of Liver Cirrhosis.

Rey I, Effendi-Ys R Med Arch. 2021; 75(3):199-203.

PMID: 34483450 PMC: 8385729. DOI: 10.5455/medarh.2021.75.199-203.

References

An P, Winkler C, Guan L, OBrien S, Zeng Z . A common HLA-DPA1 variant is a major determinant of hepatitis B virus clearance in Han Chinese. J Infect Dis. 2011; 203(7):943-7. PMC: 3068033. DOI: 10.1093/infdis/jiq154. View

Deng G, Zhou G, Zhang R, Zhai Y, Zhao W, Yan Z . Regulatory polymorphisms in the promoter of CXCL10 gene and disease progression in male hepatitis B virus carriers. Gastroenterology. 2008; 134(3):716-26. DOI: 10.1053/j.gastro.2007.12.044. View

Gangwar R, Mittal B, Mittal R . Association of interleukin-6 -174G>C promoter polymorphism with risk of cervical cancer. Int J Biol Markers. 2009; 24(1):11-6. DOI: 10.1177/172460080902400102. View

Chong W, To Y, Ip W, Yuen M, Poon T, Wong W . Mannose-binding lectin in chronic hepatitis B virus infection. Hepatology. 2005; 42(5):1037-45. DOI: 10.1002/hep.20891. View

Zhang X, Hong X, Deng G, Bai X . Single nucleotide polymorphisms and functional analysis of class II transactivator (CIITA) promoter IV in persistent HBV infection. J Clin Virol. 2007; 40(3):197-201. DOI: 10.1016/j.jcv.2007.08.016. View

Porta C, De Amici M, Quaglini S, Paglino C, Tagliani F, Boncimino A . Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann Oncol. 2007; 19(2):353-8. DOI: 10.1093/annonc/mdm448. View

Khoruts A, Stahnke L, McClain C, Logan G, Allen J . Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology. 1991; 13(2):267-76. View

Hui C, Lau G . Immune system and hepatitis B virus infection. J Clin Virol. 2006; 34 Suppl 1:S44-8. DOI: 10.1016/s1386-6532(05)80009-5. View

Hsia C, Huo T, Chiang S, Lu M, Sun C, Wu J . Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. Eur J Surg Oncol. 2006; 33(2):208-12. DOI: 10.1016/j.ejso.2006.10.036. View

10.

Alter M . Epidemiology and prevention of hepatitis B. Semin Liver Dis. 2003; 23(1):39-46. DOI: 10.1055/s-2003-37583. View

11.

Migita K, Maeda Y, Abiru S, Nakamura M, Komori A, Miyazoe S . Polymorphisms of interleukin-1beta in Japanese patients with hepatitis B virus infection. J Hepatol. 2006; 46(3):381-6. DOI: 10.1016/j.jhep.2006.09.015. View

12.

Ayada M, Ishikawa T, Okumura A, Tanabe J, Ito H, Ohashi T . Alteration of serum cytokine balances among different phases of chronic hepatitis B virus infection. Hepatol Res. 2006; 34(4):214-21. DOI: 10.1016/j.hepres.2006.01.001. View

13.

Reichner J, Mulligan J, Spisni R, Sotomayor E, ALBINA J, Bland K . Effect of IL-6 overexpression on the metastatic potential of rat hepatocellular carcinoma cells. Ann Surg Oncol. 1998; 5(3):279-86. DOI: 10.1007/BF02303786. View

14.

Napoli J, Bishop G, McCaughan G . Increased intrahepatic messenger RNA expression of interleukins 2, 6, and 8 in human cirrhosis. Gastroenterology. 1994; 107(3):789-98. DOI: 10.1016/0016-5085(94)90128-7. View

15.

Cacciola I, Cerenzia G, Pollicino T, Squadrito G, Castellaneta S, Zanetti A . Genomic heterogeneity of hepatitis B virus (HBV) and outcome of perinatal HBV infection. J Hepatol. 2002; 36(3):426-32. DOI: 10.1016/s0168-8278(01)00295-1. View

16.

Lee Y, Park U, Choi I, Yoon S, Park Y, Lee Y . Human interleukin 6 gene is activated by hepatitis B virus-X protein in human hepatoma cells. Clin Cancer Res. 1998; 4(7):1711-7. View

17.

Park B, Lee H, Kim Y, Kim J, Jung J, Kim L . Association between interleukin 6 promoter variants and chronic hepatitis B progression. Exp Mol Med. 2003; 35(2):76-82. DOI: 10.1038/emm.2003.11. View

18.

Du W, Zhen J, Zeng Z, Zheng Z, Xu Y, Qin L . Expression of interleukin-17 associated with disease progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection. Diagn Pathol. 2013; 8:40. PMC: 3598543. DOI: 10.1186/1746-1596-8-40. View

19.

Bao S, Yang W, Zhou S, Ye Z . Relationship between single nucleotide polymorphisms in -174G/C and -634C/G promoter region of interleukin-6 and prostate cancer. J Huazhong Univ Sci Technolog Med Sci. 2008; 28(6):693-6. DOI: 10.1007/s11596-008-0618-3. View

20.

Tong Y, Wang Z, Geng Y, Liu J, Zhang R, Lin Q . The association of functional polymorphisms of IL-6 gene promoter with ischemic stroke: analysis in two Chinese populations. Biochem Biophys Res Commun. 2009; 391(1):481-5. DOI: 10.1016/j.bbrc.2009.11.084. View